AUA 2024 Bladder Cancer - Results from #20

Viewing 21-40 of 57 articles

AUA 2024: Cancer Control Rates in Adequate Versus Inadequate Treatment with Adjuvant Immunotherapy Instillations with BCG

AUA 2024: Survey on Clinical Practice Patterns in the United States for Using Intravesical Chemotherapy in the Management of BCG Unresponsive Non-Muscle Invasive Bladder Cancer

AUA 2024: First Safety and Efficacy Results of the TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–muscle-Invasive Bladder Cancer with Select FGFR Alterations

AUA 2024: Efficacy of Nadofaragene Firadenovec-vncg for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Final Results From a Phase 3 Trial

AUA 2024: Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis

AUA 2024: BOND-003- Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

AUA 2024: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder Tumor

AUA 2024: SSANTROP (APRO07-2022): A Phase II Prospective, Open-Label, Multi-Center, Single Arm Study of Sasanlimab + Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients

AUA 2024: QUILT-2.005: A Comparison of Intravesical BCG in Combination with the IL-15 Superagonist N-803 to BCG Alone in Patients with BCG-Naïve NMIBC

AUA 2024: MoonRISe-1: Phase 3 Study of TAR-210, an Erdafitinib Intravesical Delivery System, Versus Intravesical Chemotherapy in Patients with Intermediate-Risk Non–Muscle-Invasive Bladder Cancer with Susceptible FGFR Alterations

AUA 2024: National Performance of Lymphadenectomy for Muscle-Invasive Urothelial Cancer and an Exploratory Analysis to Define Optimal Lymph Node Yield Based on Southwest Oncology Group S1011 Trial

AUA 2024: Impairment of the Patient’s Health-Related Quality of Life Due to a Orthotopic Neobladder After Radical Cystectomy– Defining an Age-Related Threshold

AUA 2024: Association between Enfortumab-Vedotin Related Cutaneous Reaction and Serum Albumin Levels in Patients with Advanced Urothelial Cancer

AUA 2024: Peripheral Neuropathy and Nerve Electrophysiological Changes with Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: A Prospective Multicenter Cohort Study

AUA 2024: Nivolumab plus Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone in Patients with Previously Untreated Unresectable or Metastatic Urothelial Carcinoma: Results of Analyses to Characterize Benefit in Responders from the CheckMate 901 Trial

AUA 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by First-Line Chemotherapy Regimen and Analysis of OS from Start of First-Line Chemotherapy

AUA 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-Paclitaxel Followed by Postsurgical Adjuvant NIVO in Patients with Muscle-Invasive Bladder Cancer

AUA 2024: Response to Primary Chemoablation With UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial

AUA 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer (PROGRxN-BCa)

AUA 2024: Development and Validation of Generalizable Interpretable AI Biomarkers to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer

1
2
3